Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors

Prakash Sampath, Justin Hanes, Francesco DiMeco, Betty M. Tyler, Daniel Brat, Drew M. Pardoll, Henry Brem

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Potent immune responses against malignant brain tumors can be elicited by paracrine intracranial (IC) immunotherapy with interleukin (IL)-2. Additionally, IC delivery of carmustine via biodegradable polymers has been shown to significantly prolong survival in both animal models and clinical trials. In this study, we show that the combination of paracrine immunotherapy, with nonreplicating genetically engineered tumor cells that produce IL-2, and local delivery of chemotherapy by biodegradable polymers prolongs survival in a synergistic manner in mice challenged intracranially with a lethal murine brain tumor. Animals receiving IL-2-transduced cells and polymers containing 10% 1,3-bis(2-chloroethyl)-1-nitrosourea had significantly improved survival compared with animals receiving IL-2- transduced cells or 10% 1,3-bis(2-chloroethyl)-1-nitrosourea alone. Median survival for the control group was 19 days. Survival in animals receiving IL- 2-transduced cells and 1% carboplatin-containing polymers was also significantly improved compared with either therapy alone. Histopathological examination on day 14 of animals receiving combination treatment showed rare degenerating tumor cells. In addition to tissue necrosis surrounding the polymer, a marked inflammatory reaction was observed. In long-term survivors (all animals receiving combination treatment), no tumor was observed and the inflammatory reaction was completely resolved. The brains of animals receiving combination therapy showed both tissue necrosis due to local chemotherapy and strong inflammation due to paracrine immunotherapy. The demonstration of synergy between paracrine IL-2 and local IC delivery of antineoplastic drugs is novel and may provide a combined treatment strategy for use against both primary and metastatic IC tumors.

Original languageEnglish
Pages (from-to)2107-2114
Number of pages8
JournalCancer Research
Volume59
Issue number9
Publication statusPublished - May 1 1999

Fingerprint

Brain Neoplasms
Immunotherapy
Interleukin-2
Polymers
Drug Therapy
Carmustine
Survival
Neoplasms
Necrosis
Therapeutics
Carboplatin
Antineoplastic Agents
Survivors
Animal Models
Clinical Trials
Inflammation
Control Groups
Brain

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sampath, P., Hanes, J., DiMeco, F., Tyler, B. M., Brat, D., Pardoll, D. M., & Brem, H. (1999). Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors. Cancer Research, 59(9), 2107-2114.

Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors. / Sampath, Prakash; Hanes, Justin; DiMeco, Francesco; Tyler, Betty M.; Brat, Daniel; Pardoll, Drew M.; Brem, Henry.

In: Cancer Research, Vol. 59, No. 9, 01.05.1999, p. 2107-2114.

Research output: Contribution to journalArticle

Sampath, P, Hanes, J, DiMeco, F, Tyler, BM, Brat, D, Pardoll, DM & Brem, H 1999, 'Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors', Cancer Research, vol. 59, no. 9, pp. 2107-2114.
Sampath, Prakash ; Hanes, Justin ; DiMeco, Francesco ; Tyler, Betty M. ; Brat, Daniel ; Pardoll, Drew M. ; Brem, Henry. / Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors. In: Cancer Research. 1999 ; Vol. 59, No. 9. pp. 2107-2114.
@article{9ae67d384e024f6cb0d7ce47f1da51a6,
title = "Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors",
abstract = "Potent immune responses against malignant brain tumors can be elicited by paracrine intracranial (IC) immunotherapy with interleukin (IL)-2. Additionally, IC delivery of carmustine via biodegradable polymers has been shown to significantly prolong survival in both animal models and clinical trials. In this study, we show that the combination of paracrine immunotherapy, with nonreplicating genetically engineered tumor cells that produce IL-2, and local delivery of chemotherapy by biodegradable polymers prolongs survival in a synergistic manner in mice challenged intracranially with a lethal murine brain tumor. Animals receiving IL-2-transduced cells and polymers containing 10{\%} 1,3-bis(2-chloroethyl)-1-nitrosourea had significantly improved survival compared with animals receiving IL-2- transduced cells or 10{\%} 1,3-bis(2-chloroethyl)-1-nitrosourea alone. Median survival for the control group was 19 days. Survival in animals receiving IL- 2-transduced cells and 1{\%} carboplatin-containing polymers was also significantly improved compared with either therapy alone. Histopathological examination on day 14 of animals receiving combination treatment showed rare degenerating tumor cells. In addition to tissue necrosis surrounding the polymer, a marked inflammatory reaction was observed. In long-term survivors (all animals receiving combination treatment), no tumor was observed and the inflammatory reaction was completely resolved. The brains of animals receiving combination therapy showed both tissue necrosis due to local chemotherapy and strong inflammation due to paracrine immunotherapy. The demonstration of synergy between paracrine IL-2 and local IC delivery of antineoplastic drugs is novel and may provide a combined treatment strategy for use against both primary and metastatic IC tumors.",
author = "Prakash Sampath and Justin Hanes and Francesco DiMeco and Tyler, {Betty M.} and Daniel Brat and Pardoll, {Drew M.} and Henry Brem",
year = "1999",
month = "5",
day = "1",
language = "English",
volume = "59",
pages = "2107--2114",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors

AU - Sampath, Prakash

AU - Hanes, Justin

AU - DiMeco, Francesco

AU - Tyler, Betty M.

AU - Brat, Daniel

AU - Pardoll, Drew M.

AU - Brem, Henry

PY - 1999/5/1

Y1 - 1999/5/1

N2 - Potent immune responses against malignant brain tumors can be elicited by paracrine intracranial (IC) immunotherapy with interleukin (IL)-2. Additionally, IC delivery of carmustine via biodegradable polymers has been shown to significantly prolong survival in both animal models and clinical trials. In this study, we show that the combination of paracrine immunotherapy, with nonreplicating genetically engineered tumor cells that produce IL-2, and local delivery of chemotherapy by biodegradable polymers prolongs survival in a synergistic manner in mice challenged intracranially with a lethal murine brain tumor. Animals receiving IL-2-transduced cells and polymers containing 10% 1,3-bis(2-chloroethyl)-1-nitrosourea had significantly improved survival compared with animals receiving IL-2- transduced cells or 10% 1,3-bis(2-chloroethyl)-1-nitrosourea alone. Median survival for the control group was 19 days. Survival in animals receiving IL- 2-transduced cells and 1% carboplatin-containing polymers was also significantly improved compared with either therapy alone. Histopathological examination on day 14 of animals receiving combination treatment showed rare degenerating tumor cells. In addition to tissue necrosis surrounding the polymer, a marked inflammatory reaction was observed. In long-term survivors (all animals receiving combination treatment), no tumor was observed and the inflammatory reaction was completely resolved. The brains of animals receiving combination therapy showed both tissue necrosis due to local chemotherapy and strong inflammation due to paracrine immunotherapy. The demonstration of synergy between paracrine IL-2 and local IC delivery of antineoplastic drugs is novel and may provide a combined treatment strategy for use against both primary and metastatic IC tumors.

AB - Potent immune responses against malignant brain tumors can be elicited by paracrine intracranial (IC) immunotherapy with interleukin (IL)-2. Additionally, IC delivery of carmustine via biodegradable polymers has been shown to significantly prolong survival in both animal models and clinical trials. In this study, we show that the combination of paracrine immunotherapy, with nonreplicating genetically engineered tumor cells that produce IL-2, and local delivery of chemotherapy by biodegradable polymers prolongs survival in a synergistic manner in mice challenged intracranially with a lethal murine brain tumor. Animals receiving IL-2-transduced cells and polymers containing 10% 1,3-bis(2-chloroethyl)-1-nitrosourea had significantly improved survival compared with animals receiving IL-2- transduced cells or 10% 1,3-bis(2-chloroethyl)-1-nitrosourea alone. Median survival for the control group was 19 days. Survival in animals receiving IL- 2-transduced cells and 1% carboplatin-containing polymers was also significantly improved compared with either therapy alone. Histopathological examination on day 14 of animals receiving combination treatment showed rare degenerating tumor cells. In addition to tissue necrosis surrounding the polymer, a marked inflammatory reaction was observed. In long-term survivors (all animals receiving combination treatment), no tumor was observed and the inflammatory reaction was completely resolved. The brains of animals receiving combination therapy showed both tissue necrosis due to local chemotherapy and strong inflammation due to paracrine immunotherapy. The demonstration of synergy between paracrine IL-2 and local IC delivery of antineoplastic drugs is novel and may provide a combined treatment strategy for use against both primary and metastatic IC tumors.

UR - http://www.scopus.com/inward/record.url?scp=0033135108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033135108&partnerID=8YFLogxK

M3 - Article

C2 - 10232596

AN - SCOPUS:0033135108

VL - 59

SP - 2107

EP - 2114

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 9

ER -